CDER Head Tidmarsh on Leave, Faces Lawsuit
George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research (CDER), has been placed on administrative leave amid an investigation into his personal conduct.
A report by Stat alleges that Tidmarsh used his position to financially harm Kevin Tang, a former business associate, and Aurinia Pharma, a company in which Tang is an investor.
Tidmarsh believes the probe was prompted by concerns he raised about a new fast-track programme for rapid drug approval.
- Tidmarsh was named CDER director in July.
- The lawsuit claims he abused his position to harm Tang and Aurinia Pharma.
Author's summary: CDER head Tidmarsh on leave amid lawsuit.